Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients

Rapamycin Inhibits Transforming Growth Factor β1-Induced Fibrogenesis in Primary Human Lung Fibroblasts

(2013) Yu Gao et al.   YONSEI MEDICAL JOURNAL

New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis

(2012) Isis E Fernandez et al.   LANCET

Clinical implication of protease-activated receptor-2 in idiopathic pulmonary fibrosis

(2012) Young Sik Park et al.   RESPIRATORY MEDICINE

Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes

(2011) Ji-Hoon Cho et al.   BMC Medical Genomics

Idiopathic pulmonary fibrosis

(2011) Talmadge E King et al.   LANCET

Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis

(2010) Eleonora Patsenker et al.   JOURNAL OF HEPATOLOGY

Rapamycin Prevents Transforming Growth Factor-α–Induced Pulmonary Fibrosis

(2009) Thomas R. Korfhagen et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway

(2009) Shreyas Das et al.   BMC CELL BIOLOGY

Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis

(2009) Borna Mehrad et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

(2008) Philip A. Gregory et al.   NATURE CELL BIOLOGY